the group was 28±8 (range 20-40). All patients diagnosed with IRP were negative for autoinflammatory genetic screening, while a MEFV variant (K695R het.) was detected in the FMF patient. Median duration of follow-up was 30 months (range 11-129). In table 1, demographic and clinical features are given. The median number of recurrence was 6 before anakinra treatment. No episode of pericarditis was observed in any of the patients after the initiation of anakinra. The response to anakinra persisted even after the dose was reduced to 100 mg/alternate day in 3 patients, however in 2, recurrence of pericarditis was observed and anakinra was escalated to initial dose. It was possible to discontinue corticosteroid treatment in all patients. Currently all patients continue anakinra treatment. No side effect including injection site reaction, has been observed by now.

Conclusion: Anakinra seems to be a safe and effective treatment approach for colchicine resistant recurrent pericarditis. However recurrence may occur during dose tapering.

REFERENCES:

- [1] Adler Y, et al. Colchicine treatment for recurrent pericarditis. A decade of experience. *Circulation*. 1998 2;97(21):2183-5.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.6562

FRI0617 APPLICATION OF AUTO-INFLAMMATORY DISEASE DAMAGE INDEX (ADDI) TO PATIENTS WITH FMF AND RELATED FACTORS WITH DAMAGE

Hakan Babaoglu¹, Berkan Armagan², Erdal Bodakci³, Timuçin Kaşifoğlu³, Hasan Satış¹, Nuh Atas¹, Alper Sari², Nazife Sule Yasar Bilge³, Gözde Kübra Yardımcı², Reyhan Bilici Salman¹, Levent Kılıç², Mehmet Akif Öztürk¹, Berna Goker¹, Semir Haznedaroğlu¹, Umut Kalyoncu², **abdurrahman tufan**¹.

¹Gazi University Faculty of Medicine, Department of Internal Medicine-Rheumatology, Ankara, Turkey; ²Hacettepe University Faculty of Medicine, Department of Internal Medicine-Rheumatology, Ankara, Turkey; ³Eskisehir Osmangazi University Faculty of Medicine, Department of Internal Medicine-Rheumatology, Eskisehir, Turkey

Background: Familial Mediterranean Fever (FMF) is the most frequent auto-inflammatory disease caused by MEFV gene mutations. Available reports investigated only specific components of damage such as amyloidosis. All possible organ targets of damage have not been entirely evaluated before. Such as Disease severity index which is emerged especially for FMF do not cover entire damage domains related to FMF. Recently, a new scoring system (Auto-inflammatory disease damage index) was developed and validated for autoinflammatory diseases.

Objectives: We aimed to investigate damage accrual caused by FMF and associated features with damage.

Methods: All patients recruited from FMF in Central Anatolia (FICA) cohort, which is a duplication disabled, internal and externally controlled, cross-sectional, multicenter accessible web-based cohort. This study is comprising 970 adult patients (mean age 35.3 ±12.1 years, 61.5% female). Demographic data, FMF disease characteristics, co-morbid conditions, disease complications were meticulously questioned and laboratory features and genotype data (if available) were recruited from patient files. FMF caused damage was assessed by auto-inflammatory disease damage index (ADDI) which is recently validated. Association between damage and demographic, disease and treatment characteristics were analyzed.

Results: Proportions of FMF manifestations were fever 83.1%, peritonitis 91.5%, pleuritis 47.9%, arthritis 43.3% and skin rash 26.2%. Dominant attack types were fever in 6.2%, serositis in 65.7%, musculoskeletal in 16.8% and all types of attacks were common in rest of patients. MEFV mutations were available in 814 subjects and 75.9% of these subjects were harboring M694V mutation (42.5% homozygous for M694V). Among all 63.1% patients were well responded to colchicine and 8.8% were non-responders. Median ADDI score was 1 (min 0-max 11). Most common FMF related damages were observed in musculoskeletal, reproductive and kidney domains. Chronic musculoskeletal pain was present in 49%, joint deformity in 2.9%, infertility in 6.6%, amenorrhea in 3.9%, proteinuria in 6.9%, amyloidosis in 5.9% and renal failure in 3.7% of the patients. 411 (%42.3) of patients had no damage accrual. M694V homozygous mutation, male gender and colchicine nonresponse were found to be the independent predictors of damage.

Conclusion: M694V homozygous mutation, colchicine non-response and male gender are predictors of damage and effective therapeutic interventions must be undertaken to prevent from damage in these patients.

Acknowledgement: None

Disclosure of Interests: Hakan Babaoglu: None declared, Berkan Armagan: None declared, Erdal Bodakci: None declared, Timuçin Kaşifoğlu: None declared, Hasan Satış: None declared, Nuh Atas: None declared, Alper Sari: None declared, Nazife Sule Yasar Bilge: None declared, Gözde Kübra Yardımcı: None declared, Reyhan Bilici Salman: None declared, Levent Kılıç: None declared, Mehmet Akif Öztürk: None declared, Berna Goker: None declared, Semir Haznedaroğlu: None declared, Umut Kalyoncu Grant/research support from: MSD, Roche, UCB, Novartis and Pfizer, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim, Speakers bureau: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim, **abdurrahman tufan**: None declared

DOI: 10.1136/annrheumdis-2019-eular.8197

FRI0618 ANALYSIS OF NEW REFERRALS TO A SPECIALIST UK ADULT AUTOINFLAMMATORY DISEASE SERVICE

Serdal Ugurlu¹, Philip N. Hawkins², Charalampia Papadopoulou², Tamer Rezk², Dorota Rowczenio², Helen J. Lachmann². ¹Cerrahpaşa Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey; ²UCL Division of Medicine and Royal Free Hospital London NHS Foundation Trust, National Amyloidosis Centre, London, United Kingdom

Background: Diagnosis of the systemic autoinflammatory diseases (SAIDs) requires a high index of suspicion and previous series has suggested that there are often long diagnostic delays, particularly in TRAPS and MKD.

Objectives: To look at the case mixed referred to a single adult clinic in London specialising in assessment of potential SAIDs over the course of the year of 2017.

Methods: All new referrals were accepted for clinical assessment. At the first visit patients had a full history and examination, genetic testing – varying from single gene to a 20 gene panel depending on clinical features, and laboratory testing including fortnightly blood draws for serial analysis of the hepatic acute phase response proteins, CRP and SAA over a 3 month period.

Patients with a non suggestive history, non contributory genetic testing and no evidence of inflammation accompanying symptoms were felt not to have SAIDs and referred back to their local hospitals for further management. Other cases were diagnosed based on full clinical assessment, other investigations – for example ferritin in AOSD, genetic testing results, serial monitoring of CRP and SAA and therapeutic trials, for example colchicine in presume FMF and anti IL-1 therapies in CAPS and Schnitzler's syndrome.

Results: 273 new patients were referred. Median age at referral was 37.4 years, the oldest patient was 84.3 years old and 59% were female. 174 (64%) were of northern European ancestry, 68 (25%) were eastern Mediterranean, west Asian or southern European ancestry, 19 (7%) were of south or east Asian ethnicity and 4% were of African or Afro-Caribbean ancestry. 76% of referrals were from hospital specialities. The referral source was: rheumatology 38%, general practitioner 24%, dermatology 8%, immunology 8%, gastroenterology 6%, infectious diseases 3%, clinical genetics 3%, nephrology 2%, haematology 2%, gynaecology 2%, emergency department 1%, respiratory 1%, other 2%.

After work up 135 (49.5%) were felt not to have a SAID as the cause of their symptoms. Of the remaining 138 patients who did have evidence of a SAID the diagnoses made were: FMF 33%, uncharacterised SAID 26%, CAPS 9%, AOSD 8%, recurrent idiopathic pericarditis 6%, Schnitzler's Syndrome 5%, TRAPS 4%, variant PFAPA 4%, DADA2 1%, MKD 1%, CRMO 1%, Behcets 1%, Cattleman's disease 1%.

The median interval between reported symptom onset and diagnosis were as follows: 16 yrs for FMF, 28.1 yrs for CAPS, 5.0 years for recurrent idiopathic pericarditis, 4.5 yrs for Schnitzler's Syndrome, 5.7 yrs for TRAPS, 20.5 yrs for variant PFAPA, 12.5 yrs for DADA2, 17 yrs for MKD and 2 years for CRMO.

Conclusion: This series suggests that recognition and diagnosis of the SAIDs remains a challenge. More than 1/3 of referrals were from rheumatology, referrals from primary care were almost exclusively from patients with a known family history of one the inherited syndromes. The wide variety of referring specialities reflects the diverse nature of SAIDs and the importance of almost all specialities considering the possibility of SAIDs. Only just over 50% referrals had evidence of diseases falling within the recognised SAID spectrum and 26% of these have currently uncharacterised disease with no diagnostic genetic testing. Of those in whom a diagnosis could be made there are significant diagnostic delays fortunately despite late initiation of treatment no patients had evidence of systemic AA amyloidosis.